P2D Bioscience (P2D) is a specialty pharmaceutical company focused on developing innovative drugs that fulfill unmet medical needs in the treatment of central nervous system (CNS) and pulmonary disorders including attention deficit/hyperactivity disorder (ADHD), obesity, anxiety, depression, Alzheimer’s disease, traumatic brain injury and chronic obstructive pulmonary disease (COPD). At P2D, our experienced drug development team utilizes our in-depth understanding of the clinical treatment of CNS disorders and neurodegenerative diseases to efficiently build a product portfolio of therapeutics with an improved likelihood for clinical success. Our goal is to advance a product candidate through preclinical development and clinical proof-of-concept by producing powerful and compelling clinical data and then seeking partners to complete the clinical development and commercialization process. P2D currently has a pipeline of nine drug candidates to treat ADHD, obesity and diabetes, Alzheimer’s disease, traumatic brain injury and COPD.